CoQ10 · Coenzyme Q10
A well-established mitochondrial cofactor, especially useful on statins.
Short answer
CoQ10 (Coenzyme Q10) is a mitochondrial with evidence grade B, meaning it is supported by human RCTs. We track 19 produkter containing CoQ10. Typical doses range from 100.0 to 200.0 mg per portion. The top-ranked product scores 7.5 out of 10 on our composite scale (dose, evidence, price, testing, transparency). Prices range up to $45.00 per månad.
Top CoQ10 produkter
| Product | Varumärke | Dose | Pris/mo | 3rd-party tested | Poäng |
|---|---|---|---|---|---|
| Coenzyme Q10 (CoQ10) Powder | 200.0 mg | $31.97 | No | 7.5 | |
| Ultimate Omega +CoQ10 | 100.0 mg | $40.95 | Yes | 7.5 | |
| CoQ10 120 mg | 120 mg | $45.00 | Yes | 7.4 | |
| CoQH-CF Softgels | Ubiquinol Supplement | 100.0 mg | $29.99 | Yes | 7.4 | |
| Ubiquinol CoQ-10 - 100 mg, 60 softgels | 100.0 mg | $40.99 | Yes | 7.4 |
Scores are editorial judgments, not a scientific standard. Se how we score.
What it is
Every cell needs CoQ10 to make energy. Statin cholesterol drugs deplete it, and levels drop naturally with age. Supplementing raises blood levels reliably.
Why people take it
Strongest evidence: reduces statin-associated muscle pain, improves heart-failure symptoms. Longevity benefit is a stretch, but as a mitochondrial support ingredient it's cheap, safe, and well-characterised.
Our verdict
One of the most defensible ingredients in any stack. Choose ubiquinol form if you're over 40, it absorbs better than ubiquinone.
Structure & class
2,3-dimethoxy-5-methyl-1,4-benzoquinone with 10-isoprenoid tail. Electron carrier in complex I, III of oxidative phosphorylation.
Mechanism & clinical data
Multiple RCTs (Q-SYMBIO 2014) demonstrate reduced all-cause mortality in heart failure at 300 mg/day. Meta-analyses support blood-pressure lowering and statin myopathy relief. Longevity endpoints not directly tested.
Pharmacokinetics
~33 hours in plasma.
Dose & forms
What to watch out for
Cheap CoQ10 powder in capsules has minimal absorption. Look for softgels with oil carrier or ubiquinol form.
Säkerhet limits and interactions
When a product exceeds the UL or contains an ingredient with clinically significant interactions, a "Review advised" flag appears on its product page and links here.
Where this dose comes from
The trial dose above is our editorial pick from the published human trials for this ingredient. We choose the dose that the best-available studies used on the endpoint most relevant to longevity. The range shows the lowest and highest doses tested in published trials. The landmark studies below are the papers we read to set it. You can click through and check our work.
When new trials publish, our automated sweeps flag them. If a new study materially changes the dose, we update it through editorial review and record the old dose, new dose, and the triggering study in every affected product's recommendation history. The dose is never changed automatically.
Regelverk status
Timeline
Regelverk events, evidence grade changes, and key research milestones for CoQ10, most recent first. Every entry links to its primär source.
-
EU Court sharpens the bar for botanical health claimsA Court of Justice of the European Union ruling in april 2025 further tightened the requirements for how botanical ingredients (herbs, plant extracts) can be marketed with health claims in the EU, effectively removing much of the flexibility of the on-hold list.
-
EU report identifies 117 supplement substances as potential health risksThe HoA Working Group on Food Supplements (26 European countries) published its first report evaluating 117 substances used in food supplements. Of these, 65 were assessed as likely novel foods, 6 were already regulated, 34 had insufficient data, and 12 were prioritized for Article 8 restriction under Regulation (EC) No 1925/2006. The 12 priority substances include ashwagandha, curcumin, melatonin, piperine, St. John's wort, coumarin, p-synephrine, maca, holy basil, Melaleuca, black cohosh, and L-tryptophan. The report drew on 1,500 RASFF alerts reviewed between 2017 and mid-2022.
-
Q-SYMBIO 2014 (Mortensen et al., JACC)300 mg/day in chronic HF cut major cardiovascular events 43% over 2 years.
-
EFSA rejects most CoQ10 health claimsEFSA published a scientific opinion on coenzyme Q10 health claims, rejecting claims related to energy metabolism, blood pressure, cognitive function, DNA protection, and endurance capacity. The panel concluded that a cause and effect relationship was not established for any of the claimed effects. CoQ10 remains legal as a food supplement in the EU but cannot bear authorised health claims.
-
EU Health Claims Regulation adoptedRegulation (EC) No 1924/2006 laid down harmonised rules for nutrition and health claims made on foods, including supplements. Only claims listed in the EU Register of authorised claims can be used. Rejected botanical claims are held in a separate on-hold list.
-
EU introduces the Novel Food RegulationRegulation (EC) No 258/97 required any food or food ingredient without a history of consumption in the EU before 15 maj 1997 to be authorised before being placed on the market. This is the framework that captures NMN, spermidine as a supplement ingredient, urolithin A, and many other longevity actives.
CoQ10 is a mitochondrial cofactor that helps cells generate energy, and in heart failure patients it reduced deaths in one large trial.
Verified 2026-06-23. We update this section as new peer-reviewed trials land.
Best-supported claim
CoQ10's best-supported claim comes from the Q-SYMBIO trial, a randomized, dubbelblind, multicenter trial of 420 chronic heart failure patients led by Svend Aage Mortensen, which found CoQ10 300 mg/day reduced the composite of hospitalization for worsening heart failure, cardiovascular death, or urgent transplant/mechanical support by half (hazard ratio 0.50, p=0.003), and cut all-cause mortality nearly in half (hazard ratio 0.51, p=0.018) over 2 years (https://www.jacc.org/doi/abs/10.1016/j.jchf.2014.06.008). A 2021 Cochrane review of 11 studies and 1,573 heart failure patients rated this moderate-quality evidence that CoQ10 probably reduces all-cause mortality and heart failure hospitalization (https://pmc.ncbi.nlm.nih.gov/articles/PMC8092430/). Even so, Cochrane and the American Heart Association both flag that the large treatment effect, small number of total events, and reliance on one trial for the mortality finding mean CoQ10 cannot currently be recommended in heart failure guidelines (https://www.ahajournals.org/doi/10.1161/circheartfailure.115.002639).
Not supported by the evidence base
CoQ10 is heavily marketed as a fix for statin-induced muscle pain, but the trial evidence directly contradicts this claim more often than it supports it. A 2024 metaanalys of 7 RCTs and 389 patients did find a statistically significant reduction in muscle pain intensity (weighted mean difference -0.96, p<0.05), but a 2022 metaanalys of 8 RCTs and 472 patients found no significant benefit on muscle pain or creatine kinase, and a 2020 metaanalys in Atherosclerosis similarly found no benefit over placebo (https://pubmed.ncbi.nlm.nih.gov/33999383/, https://www.thecardiologyadvisor.com/news/coq10-therapy-may-not-improve-statin-adherence-or-relieve-associated-muscle-pain-in-statin-associated-myalgia/). The literature on this specific claim is genuinely split roughly down the middle depending on which trials are pooled, which means CoQ10's anti-statin-myalgia reputation outpaces the actual consistency of the data. Marketing for skin anti-aging and general energy also draws on small, often industry-adjacent studies rather than the larger heart failure evidence base that is CoQ10's strongest support.
Typical dose
100-300 mg/day, split into 2-3 doses; heart failure trials used 300 mg/day (100 mg three times daily)
Säkerhet
CoQ10 has a strong long-term safety record, including 2-year use in heart failure patients on standard medications without excess adverse events versus placebo. The Cochrane review found low-quality but inconclusive evidence regarding myocardial infarction or stroke risk, and no signal of harm (https://pmc.ncbi.nlm.nih.gov/articles/PMC8092430/). CoQ10 may reduce the anticoagulant effect of warfarin due to its structural similarity to vitamin K.
Interactions worth flagging
- warfarin and other blood thinners
- blood pressure medications
- chemotherapy agents (theoretical antioxidant interference)
Three recent studies to know
-
The Effect of Coenzyme Q10 on Morbidity and Mortality in Chronic Heart Failure: Results From Q-SYMBIO: A Randomized Double-Blind TrialLäs studie →
-
Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematisk översikt and metaanalysLäs studie →
-
Coenzyme Q10 for heart failureLäs studie →
Landmark studies
-
Q-SYMBIO 2014 (Mortensen et al., JACC)
300 mg/day in chronic HF cut major cardiovascular events 43% over 2 years.
Läs studie →
Found in these produkter (19)
Alla produkter in our catalog that contain CoQ10, ranked by our overall score. Ranking is editorial, never paid.
Buying guides and comparisons
Related ingredients
Se alla in Mitochondrial →Molekyler in the same class, plus the actives most often formulated alongside CoQ10 in our catalogue.
Frequently asked questions
What is CoQ10?
Every cell needs CoQ10 to make energy. Statin cholesterol drugs deplete it, and levels drop naturally with age. Supplementing raises blood levels reliably.
What dose of CoQ10 should I take?
The trial dose in published human studies is 200 mg per dag, with a range of 100 to 300 mg per dag. Always consult a qualified clinician before starting any supplement.
Is CoQ10 safe?
Cheap CoQ10 powder in capsules has minimal absorption. Look for softgels with oil carrier or ubiquinol form.
What is the best CoQ10 supplement?
We track 19 produkter containing CoQ10. The top-ranked product scores 7.5 out of 10 on our composite scale, which evaluates dose, evidence, price, third-party testing, and transparency. See the comparison table above. Scores are editorial judgments, not a scientific standard.
What is the evidence grade for CoQ10?
CoQ10 has evidence grade B, meaning it is supported by human RCTs. Grade A means replicated human RCTs with hard endpoints. Grade B means human RCTs with biomarker outcomes. Grade C means mixed or small human trials. See our evidence grading methodology.
Data verification
Bevisning grades are reviewed when new human RCTs are published. Product counts update automatically as new produkter are added. Dose ranges reflect published trial data, not brand recommendations. Read how we verify.